{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:07:32Z","timestamp":1746245252310,"version":"3.40.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01531-w","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:56:11Z","timestamp":1745589371000},"page":"348-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines"],"prefix":"10.1007","volume":"43","author":[{"given":"Reyhane","family":"Piri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoo","family":"Shahidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5339-7180","authenticated-orcid":false,"given":"Zahra","family":"Pooraskari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-8549","authenticated-orcid":false,"given":"Sina","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"9","key":"1531_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12032-024-02465-8","volume":"41","author":"A Kooshari","year":"2024","unstructured":"Kooshari A et al (2024) Tetrahydroisoquinoline reduces angiogenesis by interacting myeloma cells with HUVECs mediated by extracellular vesicles. Med Oncol 41(9):217","journal-title":"Med Oncol"},{"key":"1531_CR2","doi-asserted-by":"publisher","first-page":"1015402","DOI":"10.3389\/fonc.2022.1015402","volume":"12","author":"V Raimondi","year":"2022","unstructured":"Raimondi V et al (2022) Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease. Front Oncol 12:1015402","journal-title":"Front Oncol"},{"key":"1531_CR3","doi-asserted-by":"publisher","unstructured":"Feng X et al (2015) Detection of serum DKK1 in multiple myeloma and myeloma bone disease.\u00a0Zhonghua Xue Ye Xue Za Zhi.\u00a036(8):682\u20135. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2015.08.011","DOI":"10.3760\/cma.j.issn.0253-2727.2015.08.011"},{"issue":"9","key":"1531_CR4","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H et al (2020) Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist 25(9):e1406\u2013e1413","journal-title":"Oncologist"},{"issue":"7\u20138","key":"1531_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.20344\/amp.19037","volume":"36","author":"C Jo\u00e3o","year":"2023","unstructured":"Jo\u00e3o C et al (2023) Multiple Myeloma Treatment Guidelines by the Portuguese Group of Multiple Myeloma. Acta Med Port 36(7\u20138):517\u2013526","journal-title":"Acta Med Port"},{"issue":"9","key":"1531_CR6","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ et al (2018) Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol 4(9):1221\u20131227","journal-title":"JAMA Oncol"},{"issue":"4","key":"1531_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41417-022-00450-9","volume":"30","author":"L Du","year":"2023","unstructured":"Du L, Liu W, Pichiorri F, Rosen ST (2023) SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene Ther 30(4):567\u2013574. https:\/\/doi.org\/10.1038\/s41417-022-00450-9","journal-title":"Cancer Gene Ther"},{"issue":"22","key":"1531_CR8","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T et al (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380(22):2104\u20132115","journal-title":"N Engl J Med"},{"issue":"1","key":"1531_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/cells12010187","volume":"12","author":"J Kalous","year":"2023","unstructured":"Kalous J, Aleshkina D (2023) Multiple Roles of PLK1 in Mitosis and Meiosis. Cells 12(1):187","journal-title":"Cells"},{"key":"1531_CR10","doi-asserted-by":"publisher","first-page":"917366","DOI":"10.3389\/fonc.2022.917366","volume":"12","author":"M-W Wang","year":"2022","unstructured":"Wang M-W et al (2022) Polo-like kinase 1 as a potential therapeutic target and prognostic factor for various human malignancies: A systematic review and meta-analysis. Front Oncol 12:917366","journal-title":"Front Oncol"},{"issue":"70","key":"1531_CR11","doi-asserted-by":"publisher","first-page":"114474","DOI":"10.18632\/oncotarget.22967","volume":"8","author":"C Murga-Zamalloa","year":"2017","unstructured":"Murga-Zamalloa C et al (2017) Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget 8(70):114474","journal-title":"Oncotarget"},{"issue":"7","key":"1531_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/jclinpath-2016-203656","volume":"69","author":"WTW Ng","year":"2016","unstructured":"Ng WTW et al (2016) Molecular interactions of polo-like kinase 1 in human cancers. J Clin Pathol 69(7):557\u2013562","journal-title":"J Clin Pathol"},{"issue":"3","key":"1531_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3892\/or.2017.5417","volume":"37","author":"YF Tao","year":"2017","unstructured":"Tao YF et al (2017) Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. Oncol Rep 37(3):1419\u20131429","journal-title":"Oncol Rep"},{"issue":"1","key":"1531_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/leu.2014.222","volume":"29","author":"BT Gjertsen","year":"2015","unstructured":"Gjertsen BT, Sch\u00f6ffski P (2015) Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 29(1):11","journal-title":"Leukemia"},{"issue":"13","key":"1531_CR15","doi-asserted-by":"publisher","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","volume":"286","author":"CC Bjorklund","year":"2011","unstructured":"Bjorklund CC et al (2011) Evidence of a role for activation of Wnt\/\u03b2-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286(13):11009\u201311020","journal-title":"J Biol Chem"},{"issue":"7","key":"1531_CR16","doi-asserted-by":"publisher","first-page":"1900376","DOI":"10.1002\/ardp.201900376","volume":"353","author":"D Xiao","year":"2020","unstructured":"Xiao D et al (2020) Design and synthesis of new lenalidomide analogs via Suzuki cross-coupling reaction. Arch Pharm 353(7):1900376","journal-title":"Arch Pharm"},{"issue":"6","key":"1531_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/ejh.12192","volume":"91","author":"AJ Greenberg","year":"2013","unstructured":"Greenberg AJ et al (2013) Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. Eur J Haematol 91(6):504\u2013513","journal-title":"Eur J Haematol"},{"issue":"9","key":"1531_CR18","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/1535-7163.MCT-11-1036","volume":"11","author":"JQ Shi","year":"2012","unstructured":"Shi JQ et al (2012) MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther 11(9):2045\u20132053","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1531_CR19","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1535-7163.1631.3.12","volume":"3","author":"F Di Nicolantonio","year":"2004","unstructured":"Di Nicolantonio F et al (2004) The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther 3(12):1631\u20131637","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"1531_CR20","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3324\/haematol.2013.084434","volume":"98","author":"SA Hartsink-Segers","year":"2013","unstructured":"Hartsink-Segers SA et al (2013) Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica 98(10):1539","journal-title":"Haematologica"},{"issue":"8_Supplement","key":"1531_CR21","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1158\/1538-7445.AM2011-3573","volume":"71","author":"K Lasky","year":"2011","unstructured":"Lasky K et al (2011) A small molecule PLK1 inhibitor, MLN0905, yields broad anti-tumor activity in human xenograft tumor models, and synergizes with taxane therapy. Cancer Res 71(8_Supplement):3573\u20133573","journal-title":"Cancer Res"},{"issue":"18","key":"1531_CR22","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","volume":"69","author":"L Escoubet-Lozach","year":"2009","unstructured":"Escoubet-Lozach L et al (2009) Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Can Res 69(18):7347\u20137356","journal-title":"Can Res"},{"issue":"2","key":"1531_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3892\/ol.2012.1054","volume":"5","author":"K Kim","year":"2013","unstructured":"Kim K et al (2013) Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett 5(2):588\u2013592","journal-title":"Oncol Lett"},{"issue":"5","key":"1531_CR24","first-page":"1580","volume":"43","author":"Y Hanashima","year":"2020","unstructured":"Hanashima Y et al (2020) Antitumor effect of lenalidomide in malignant glioma cell lines. Oncol Rep 43(5):1580\u20131590","journal-title":"Oncol Rep"},{"issue":"8","key":"1531_CR25","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1158\/2326-6066.CIR-15-0291","volume":"4","author":"RL Browning","year":"2016","unstructured":"Browning RL et al (2016) Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunol Res 4(8):698\u2013707","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"1531_CR26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4161\/cc.8.3.7651","volume":"8","author":"N-N Kreis","year":"2009","unstructured":"Kreis N-N et al (2009) Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21WAF1\/CIP1. Cell Cycle 8(3):460\u2013472","journal-title":"Cell Cycle"},{"issue":"10","key":"1531_CR27","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1038\/cddis.2013.386","volume":"4","author":"D Neise","year":"2013","unstructured":"Neise D et al (2013) The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK-and p53-independent accumulation of p21WAF1\/CIP1. Cell Death Dis 4(10):e859\u2013e859","journal-title":"Cell Death Dis"},{"issue":"5","key":"1531_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10495-021-01667-z","volume":"26","author":"M Li","year":"2021","unstructured":"Li M (2021) The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseases. Apoptosis 26(5):235\u2013247","journal-title":"Apoptosis"},{"key":"1531_CR29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10495-015-1127-z","volume":"20","author":"Y Li","year":"2015","unstructured":"Li Y et al (2015) PUMA-mediated mitochondrial apoptotic disruption by hypoxic postconditioning. Apoptosis 20:1026\u20131032","journal-title":"Apoptosis"},{"key":"1531_CR30","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s12094-013-1010-8","volume":"15","author":"W Cai","year":"2013","unstructured":"Cai W et al (2013) Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance. Clin Transl Oncol 15:818\u2013824","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"1531_CR31","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1021\/pr5002516","volume":"13","author":"BD Cholewa","year":"2014","unstructured":"Cholewa BD et al (2014) Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAFV600E mutant melanoma cells. J Proteome Res 13(11):5041\u20135050","journal-title":"J Proteome Res"},{"key":"1531_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10495-011-0670-5","volume":"17","author":"C Brosseau","year":"2012","unstructured":"Brosseau C et al (2012) The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. Apoptosis 17:164\u2013173","journal-title":"Apoptosis"},{"issue":"5","key":"1531_CR33","first-page":"6469","volume":"15","author":"LL Yin","year":"2018","unstructured":"Yin LL et al (2018) Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro. Oncol Lett 15(5):6469\u20136474","journal-title":"Oncol Lett"},{"issue":"3","key":"1531_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.leukres.2010.09.027","volume":"35","author":"Z Qian","year":"2011","unstructured":"Qian Z et al (2011) Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 35(3):380\u2013386","journal-title":"Leuk Res"},{"issue":"4","key":"1531_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/hon.2179","volume":"33","author":"M Cosenza","year":"2015","unstructured":"Cosenza M et al (2015) The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines. Hematol Oncol 33(4):166\u2013175","journal-title":"Hematol Oncol"},{"issue":"5","key":"1531_CR36","doi-asserted-by":"publisher","first-page":"101960","DOI":"10.1016\/j.xcrp.2024.101960","volume":"5","author":"J Wang","year":"2024","unstructured":"Wang J et al (2024) Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN. Cell Rep Phys Sci 5(5):101960","journal-title":"Cell Rep Phys Sci"},{"issue":"3","key":"1531_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ijc.23990","volume":"124","author":"YB Feng","year":"2009","unstructured":"Feng YB et al (2009) Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 124(3):578\u2013588","journal-title":"Int J Cancer"},{"key":"1531_CR38","doi-asserted-by":"publisher","first-page":"1286585","DOI":"10.3389\/fonc.2023.1286585","volume":"13","author":"AK Siraj","year":"2024","unstructured":"Siraj AK et al (2024) PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer. Front Oncol 13:1286585","journal-title":"Front Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01531-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01531-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01531-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:39:59Z","timestamp":1746193199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01531-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01531-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Iran University of Medical Science, Tehran, Iran (Code: IR.IUMS.REC.1401.526).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"To ensure the highest quality of writing, this article used Ginger software to refine the language, improve clarity, enhance readability, and perform spelling and grammar checks. Finally, the entire article was reviewed and approved by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement"}}]}}